EcoDrugPlus

Malt1 Paracaspase

Ensembl ID : ENSLBEG00000026118
Gene Symbol: MALT1
3 Cross references
195 Possible Orthologues:

Map Kinase-Activated Protein Kinase 2-Like

Ensembl ID : ENSLBEG00000009647
Gene Symbol: LOC109980997
3 Cross references
174 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSLBEG00000012856
Gene Symbol: MAPKAPK2
4 Cross references
187 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSLBEG00000017597
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSLBEG00000026872
Gene Symbol: LOC110000620
3 Cross references
208 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSLBEG00000016335
Gene Symbol: MDM2
3 Cross references
275 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSLBEG00000003043
Gene Symbol: MET
3 Cross references
205 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSLBEG00000024545
Gene Symbol: MLST8
3 Cross references
199 Possible Orthologues:

Nad(P)h Dehydrogenase [Quinone] 1-Like

Ensembl ID : ENSLBEG00000016279
Gene Symbol: LOC109977952
4 Cross references
186 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSLBEG00000022644
Gene Symbol: NPC1L1
4 Cross references
189 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSLBEG00000009523
Gene Symbol: LOC109993012
3 Cross references
192 Possible Orthologues:

P2x Purinoceptor 4-Like

Ensembl ID : ENSLBEG00000007397
Gene Symbol: LOC110002853
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).